Flow-mediated dilation test market seen growing to $100 million by 2030

The global market for flow-mediated dilation testing is projected to rise from $70 million in 2025 to $100 million by 2030, driven by growing cardiovascular disease, diabetes and obesity rates. North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - Flow-mediated dilation testing is becoming more relevant as healthcare systems look for earlier ways to detect cardiovascular risk and endothelial dysfunction. - The market’s projected growth reflects rising demand for non-invasive tools that can support prevention, risk screening and vascular monitoring.

What happened: - The Business Research Company released its Flow-Mediated Dilation Test Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the market will grow from $0.07 billion in 2025 to $0.08 billion in 2026. - It projects the market will reach $0.1 billion by 2030. - The report puts the market’s 2025-2030 CAGR at 6.5%. - A free sample of the report is available. - The full market report is also available.

The details: - The flow-mediated dilation test is a non-invasive ultrasound procedure that evaluates vascular endothelial function. - The test measures the percentage change in brachial artery diameter after a short period of ischemia caused by a blood pressure cuff. - The procedure assesses the endothelium’s ability to release nitric oxide in response to shear stress. - The report says the test serves as an early marker for cardiovascular diseases and atherosclerosis. - Historic growth was driven by rising cardiovascular disease and atherosclerosis prevalence, higher awareness of early cardiovascular risk assessment, stronger demand for non-invasive diagnostics, increased use of vascular health monitoring in research, and adoption of ultrasound-based endothelial function testing. - The report says future growth will be supported by AI-driven vessel measurement technologies, demand for personalized cardiovascular risk prediction, and integration of advanced imaging software with diagnostic systems. - Preventive healthcare screening programs are expanding, and automated endothelial function assessment tools are gaining traction in clinical settings. - Automated flow-mediated dilation analysis and improved imaging technologies are among the leading trends cited in the report. - North America held the largest market share in 2025. - Asia-Pacific is expected to record the fastest growth during the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - The market forecast tracks a broader shift toward prevention-focused cardiovascular care, where clinicians want faster and less invasive ways to flag risk earlier. - Rising rates of diabetes, obesity and multiple chronic conditions are expanding the patient pool that could benefit from endothelial function testing. - The report’s emphasis on automation and AI suggests buyers are looking for speed, consistency and easier clinical workflow integration, not just measurement accuracy. - CDC data cited in the report said cardiovascular disease caused 919,032 deaths in 2023, or about one in every three U.S. deaths. - The UK’s National Diabetes Audit 2024-25 reported that 43.0% of people with type 1 diabetes in England completed all eight recommended care processes by March 2025. - An August 2025 study in the International Journal of Population Data Science found higher average comorbidity counts in the most deprived populations than in less deprived groups, including 1.84 versus 1.49 among the groups studied.

What's next: - The report expects continued adoption of automated endothelial function tools in clinical settings. - Market growth will likely hinge on wider use of advanced imaging, AI-enabled measurement and preventive screening programs. - Asia-Pacific’s faster growth could reshape regional demand patterns over the forecast period.

The bottom line: - Flow-mediated dilation testing is moving from a niche diagnostic tool toward a broader role in preventive cardiovascular care, and the market outlook reflects that shift.